 SEATTLE, April 08, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS, a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that an ovarian cancer patient has begun treatment with Atossas proprietary oral Endoxifen. The FDA previously issued a Safe to Proceed letter under their expanded access pathway, permitting the use of Atossas oral Endoxifen in this patient. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. 